Tet Methylcytosine Dioxygenase 3 Protein
Overview
TET3 (Ten-Eleven Translocation 3), also known as methylcytosine dioxygenase 3, is an iron (Fe2+) and α-ketoglutarate-dependent enzyme that catalyzes the oxidation of 5-methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC) in DNA. The TET family comprises three members in mammals—TET1, TET2, and TET3—all sharing similar catalytic domains and enzymatic functions. TET3 is encoded by the TET3 gene located on chromosome 2p13 and is particularly abundant in neurons and neural progenitor cells. As an epigenetic modulator, TET3 plays a crucial role in DNA methylation dynamics, serving as a bridge between stable DNA methylation states and active demethylation processes essential for gene regulation and neuronal function.
Function/Biology
TET3 catalyzes the sequential oxidation of methylated cytosines through a well-characterized enzymatic pathway. The enzyme converts 5mC to 5hmC through its dioxygenase activity, utilizing Fe2+ and α-ketoglutarate as cofactors and producing succinate and carbon dioxide as byproducts. Subsequently, 5hmC can undergo further oxidation to 5-formylcytosine (5fC) and 5-carboxylcytosine (5caC), modifications that are recognized by thymine DNA glycosylase (TDG) for base excision repair-mediated conversion back to unmodified cytosine. This iterative process represents active DNA demethylation and allows dynamic regulation of gene expression patterns.
...Tet Methylcytosine Dioxygenase 3 Protein
Overview
TET3 (Ten-Eleven Translocation 3), also known as methylcytosine dioxygenase 3, is an iron (Fe2+) and α-ketoglutarate-dependent enzyme that catalyzes the oxidation of 5-methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC) in DNA. The TET family comprises three members in mammals—TET1, TET2, and TET3—all sharing similar catalytic domains and enzymatic functions. TET3 is encoded by the TET3 gene located on chromosome 2p13 and is particularly abundant in neurons and neural progenitor cells. As an epigenetic modulator, TET3 plays a crucial role in DNA methylation dynamics, serving as a bridge between stable DNA methylation states and active demethylation processes essential for gene regulation and neuronal function.
Function/Biology
TET3 catalyzes the sequential oxidation of methylated cytosines through a well-characterized enzymatic pathway. The enzyme converts 5mC to 5hmC through its dioxygenase activity, utilizing Fe2+ and α-ketoglutarate as cofactors and producing succinate and carbon dioxide as byproducts. Subsequently, 5hmC can undergo further oxidation to 5-formylcytosine (5fC) and 5-carboxylcytosine (5caC), modifications that are recognized by thymine DNA glycosylase (TDG) for base excision repair-mediated conversion back to unmodified cytosine. This iterative process represents active DNA demethylation and allows dynamic regulation of gene expression patterns.
In neurons, TET3 localizes predominantly to the nucleus and associates with chromatin, particularly at promoter regions and gene bodies of actively transcribed genes. The protein contains a catalytic DIOXYGENASE domain in its C-terminal region, flanked by regulatory domains that modulate its enzymatic activity. TET3 interacts with various chromatin-associated proteins, histone deacetylases, and transcriptional machinery, integrating epigenetic signals with transcriptional control mechanisms. During development and differentiation, TET3 exhibits dynamic expression patterns, with particularly high levels during neural differentiation and synaptic plasticity.
Role in Neurodegeneration
Emerging evidence implicates dysregulated TET3 function in several neurodegenerative diseases. In Alzheimer's disease, aberrant DNA methylation patterns at genes associated with amyloid metabolism and neuroinflammation suggest potential TET3 dysfunction. Altered 5hmC levels have been detected in postmortem brain tissue from Alzheimer's patients, particularly in regions vulnerable to neurodegeneration. Abnormal TET3 activity may compromise the transcriptional plasticity required for synaptic maintenance and neuroprotective gene expression.
In Parkinson's disease, disrupted epigenetic regulation contributes to dopaminergic neuron vulnerability. TET3 dysregulation could impair the expression of genes involved in mitochondrial function, oxidative stress response, and dopamine metabolism—all central to dopaminergic pathology. Similarly, in frontotemporal dementia and other tauopathies, altered methylation dynamics at tau-related and inflammatory gene loci may reflect impaired TET3-mediated demethylation. Additionally, age-related decline in TET3 function could represent a molecular mechanism underlying the age-dependent progression of neurodegenerative disorders.
Molecular Mechanisms
TET3-mediated epigenetic remodeling influences neurodegeneration through multiple interconnected mechanisms. The enzyme regulates genes encoding neurotrophic factors, synaptic proteins, and antioxidant enzymes critical for neuronal survival. Altered TET3 activity can compromise the expression of brain-derived neurotrophic factor (BDNF) and other neuroprotective factors, reducing neuronal resilience to proteotoxic stress. Furthermore, TET3 participates in the regulation of inflammatory response genes; its dysregulation may exacerbate neuroinflammation by altering the methylation status of genes encoding pro-inflammatory cytokines and microglial activation markers.
TET3 also influences genes regulating amyloid-β and tau metabolism, directly linking its activity to hallmark pathologies. Through its interaction with histone deacetylases and other chromatin modifiers, TET3 establishes feedback loops that coordinate DNA methylation with histone modifications, maintaining epigenetic stability in aging neurons. Impaired TET3 function compromises this homeostatic regulation, permitting aberrant gene expression patterns that promote neurodegeneration.
Clinical/Research Significance
Understanding TET3 biology offers potential therapeutic opportunities for neurodegenerative diseases. Pharmacological modulation of TET3 activity or enhancement of demethylation capacity at disease-relevant genes represents a novel therapeutic strategy. Biomarker studies measuring 5hmC levels or TET3 protein expression in cerebrospinal fluid or blood could provide diagnostic or prognostic information. Animal models with conditional TET3 deletion in neurons have demonstrated enhanced vulnerability to excitotoxicity and acceler